|Articles|June 15, 2015
- BioPharm International-06-15-2015
- Volume 2015 eBook
- Issue 1
Taking a “Development-by-Design” Approach to Cell Therapies
Author(s)Agnes Shanley
Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.
Advertisement
Cell therapies, both autologous and allogeneic, have come a long way in just a few years. Failures, often in clinical stages, have been traced to problems with manufacturing and failure to understand process requirements earlier in the development process.
Download
.
Articles in this issue
over 10 years ago
QRM Tools for Contract Biomanufacturingover 10 years ago
Fill/Finish Trendsover 10 years ago
Biopharma Advances Demand Specialized Expertiseover 10 years ago
Protecting Intellectual Property in Engagements with CMOsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5
